Pfizer's LITFULO Shows Efficacy in Vitiligo Trials
Pfizer presented results from two Phase 3 trials showing LITFULO (ritlecitinib) improved facial and total body repigmentation in patients with nonsegmental vitiligo.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Full Transcript: Pfizer Q2 2026 Earnings Call
Pfizer (NYSE: PFE ) released second-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. Access the full call at Summary Full Transcript OPERATOR Good day everyone and wel